<?xml version="1.0" encoding="UTF-8"?>
<p>Flu-v vaccine contains multiple highly conserved T cell epitopes derived from NP, matrix proteins (M1 and M2) from influenza A and NP from influenza B viruses and are conserved across most influenza viruses with high population coverage [
 <xref rid="B81-vaccines-07-00045" ref-type="bibr">81</xref>,
 <xref rid="B82-vaccines-07-00045" ref-type="bibr">82</xref>]. The phase II clinical trials with adjuvant+Flu-v triggered the T-cellular responses and also induced antibody response [
 <xref rid="B83-vaccines-07-00045" ref-type="bibr">83</xref>].
</p>
